Digistain®

Digistain® company information, Employees & Contact Information

Explore related pages

Related company profiles:

Digistain ® - Leading digital transformation in cancer diagnostics - radically faster gold standard risk scoring analytics at a dramatically lower cost A Digital Solution To Cancer Grading And Prognosis approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), DIGISTAIN® is a patented risk profiling test for hormone receptor-positive breast cancer patients. Digistain’s easy-to-read report provides both physician and patient clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required. The MHRA approved DIGISTAIN technology is based on 15 years of research and development pioneered by respected cancer research scientists at Imperial College with Professor Chris Phillips of the Biomedical Optics Division and Cancer Research UK (CRUK) with Professor Sir Nicholas Wright of Barts Hospital London, Head of Histopathology at CRUK and ex-president of the Pathological Society of Great Britain.

Company Details

Employees
22
Address
Unit 101, Interchange Business Park,, Howard Way,united Kingdom
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Newport Pagnell,
Looking for a particular Digistain® employee's phone or email?

Digistain® Questions

News

Infrared spectrometry guides cancer treatment - Nature

Infrared spectrometry guides cancer treatment Nature

Digistain gains clinical data to support rapid breast cancer assessment method - Imperial College London

Digistain gains clinical data to support rapid breast cancer assessment method Imperial College London

Sofia Angels Ventures Helps UK Medtech Startup Digistain Raise $1M to Fight Breast Cancer - The Recursive

Sofia Angels Ventures Helps UK Medtech Startup Digistain Raise $1M to Fight Breast Cancer The Recursive

Core Diagnostics, Digistain collaborate to bring breast cancer risk profiling technology to India, Nepal, Bh.. - ET HealthWorld

Core Diagnostics, Digistain collaborate to bring breast cancer risk profiling technology to India, Nepal, Bh.. ET HealthWorld

UK Pushes Quantum Technology Into Healthcare, Eyes 2030 Target - The Quantum Insider

UK Pushes Quantum Technology Into Healthcare, Eyes 2030 Target The Quantum Insider

‘Digistain’ technology offers revolution in detailed cancer diagnosis - Imperial College London

‘Digistain’ technology offers revolution in detailed cancer diagnosis Imperial College London

EastEnders' Sam Womack on cancer journey and brutal chemotherapy - Metro.co.uk

EastEnders' Sam Womack on cancer journey and brutal chemotherapy Metro.co.uk

Rapid breast cancer screening technology could stop unnecessary chemotherapy - Imperial College London

Rapid breast cancer screening technology could stop unnecessary chemotherapy Imperial College London

Technology that could detect cancer more accurately wins Innovation Award | Imperial News - Imperial College London

Technology that could detect cancer more accurately wins Innovation Award | Imperial News Imperial College London

Research, enterprise and education excellence recognised by Institute of Physics - Imperial College London

Research, enterprise and education excellence recognised by Institute of Physics Imperial College London

Top Digistain® Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant